The CDC has summarized present and updated guidelines on dengue and Zika virus diagnostic testing in patients with a clinically compatible illness who live in or recently traveled to an endemic area.
The TIDES trial is investigating the safety and efficacy of 2 doses of TAK-003 in preventing dengue fever caused by any of the 4 dengue virus serotypes.
Two Phase 3 trials conducted in Asia and Latin America assessed the efficacy of the vaccine in >35,000 individuals aged 2 to 16 years.
The failure mode and effect analysis methodology may facilitate protocols for new control that would benefit dengue detection and assessment for the 2020 Olympics.
The principles of “trolleyology” can be used to understand hesitancy among certain individuals to vaccinate against the Dengue virus.
Diagnostic indicators including conjunctivitis, platelet count, and monocyte count can be used to reliably distinguish between Zika virus and dengue fever.
A tetravalent dengue vaccine protective against severe virologically confirmed dengue and hospitalization because of VCD for 5 years in patients with previous dengue exposure before vaccination.
Vector-borne diseases represent an increasing problem in the United States, with a more than 2-fold increase in the number of annual reports from 2004 to 2016.
Without proactive measures and response, the changing climate is projected to continue to adversely affect the global incidence and distribution of infectious diseases and cause 250,000 additional deaths per year between 2030 and 2050.
A rapid immunochromatography approach can differentiate dengue and Zika virus cases
